Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash.
Founded 20 years ago, Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Thermo Fisher executive vice-president Michel Lagarde said: “The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America.
“In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors.
“The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”
The viral vector manufacturing business offers over 7,000m² of advanced clinical and commercial manufacturing capacity.
With two locations in Seneffe and Gosselies, Henogen has around 400 employees with extensive operational and technical proficiency in various viral vector classes.
Novasep president and CEO Michel Spagnol said: “Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher.
“Our talented employees will bring deep expertise to an organisation that shares our commitment to providing ground-breaking new medicines to patients.”
The business will be part of the Pharma Services business within the Laboratory Products and Services Segment.
In March 2019, Thermo Fisher Scientific signed a definitive agreement to acquire viral vector manufacturing company Brammer Bio for a cash consideration of around $1.7bn.
Brammer Bio is focused on the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.
by Pharmaceutical-Technology.com
Source: pharmaceutical-technology.com
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
